PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study
Stopped Study no longer needed because eligible subjects may receive treatment with cobomarsen in a crossover arm of the SOLAR clinical trial (NCT03713320)
Conditions
- Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Interventions
Sponsor
miRagen Therapeutics, Inc.